Yup.
“Here is a list of the current top patents for the most popular GLP1 Receptor Agonist formulations that are due to expire. Exenatide (Byetta/Bydureon) Original patent expired in 2016; Extended-release formulation patent expires in 2025; Liraglutide (Victoza) Patent expired in 2024; Semaglutide (Ozempic/Wegovy) Core patents expire in 2026…”
Yes, investors know that drug stocks are more volatile because studies continue on new promising drugs. Occasionally they hit a home run but other times results are less than expected and the stock takes a dive.
This just happened to Novo Nordisk when a weight loss drug gave 22% wt loss rather than the 25% expected. The stock tanked. A buying opportunity for those willing to accept the risk.